10 Best Large Cap Value Stocks to Invest In

4. Gilead Sciences, Inc. (NASDAQ:GILD)

Forward P/E as of July 11: ~13.7x

Market Cap as of July 11: $136.3 Billion

Number of Hedge Fund Holders: 79

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a “Buy” rating on the company’s stock, retaining a price objective of $120.00. The analyst’s rating is backed by a combination of factors associated with the promising prospects of the new drug, Yeztugo. The drug, which is also known as Lenacapavir, was recently approved by the FDA for use as a monotherapy in preventing HIV, which can significantly drive Gilead Sciences, Inc. (NASDAQ:GILD)’s growth, added the firm’s analyst.

Furthermore, the innovation in Yeztugo’s dosing paradigm is expected to enhance patient adherence as well as expand the PrEP market. Despite the concerns related to the drug’s pricing, the analyst believes that the perceived financial burden might be mitigated by the insurance coverage. The analyst has also highlighted Gilead Sciences, Inc. (NASDAQ:GILD)’s strategic efforts to address logistical challenges. Overall, such factors, together with the drug’s clinical differentiation and market receptivity, support the analyst’s favourable outlook for the company’s stock.

Notably, the company has announced a strategic partnership agreement with the Global Fund to fight AIDS, Tuberculosis, and Malaria to supply lenacapavir, Gilead Sciences, Inc. (NASDAQ:GILD)’s twice-yearly injectable HIV-1 capsid inhibitor, for preventing HIV as pre-exposure prophylaxis (PrEP).

Impax Asset Management, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:

“Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.”